You are here: Industry Insights > Market News > Lupin launches Nitazoxanide Tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Lupin launches Nitazoxanide Tablets

expresspharmaMarch 11, 2021

Tag: lupin , Alinia , romark , Nitazoxanide Tablets

Favorites

Lupin announced the launch of the authorized generic version of Alinia (nitazoxanide) Tablets, 500 mg of Romark Laboratories.

Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhoea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.

Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of $56 million in the US. (IQVIA MAT January 2021).

Previous:CEPI plans 100-day target for new vaccines against emerging disease epidemics

Next:Scientists at IIT Madras identify energy deficiency in brain cells as major cause for Parkinson’s Disease

The life science and biotech PR distribution service

Biotech NewswireMay 06, 2024

Alfred Merz, PhD, has been appointed as Chief Operating Officer effective May 1st, 2024.

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Lupin launches Nitazoxanide Tablets | Pharmasources.com

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

The study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP.

Lupin launches Nitazoxanide Tablets

Related News

The life science and biotech PR distribution service

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

You may like